Multiple SclerosisNCT03552185
Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies
An observational study of Multiple Sclerosis, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2018to 15 Jun 2018
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: Egyptian patients with Clinically Definite Multiple sclerosis according McDonald's criteria 2017 Selected patients will be all Multiple Sclerosis patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval (January 2018- June 2018) with an estimate of 100 patients
Who may be able to join
- Patients diagnosed with Multiple Sclerosis
Who cannot join
- Local causes of Dysphagia excluded by proper history taking, proper clinical examination (e.g.; esophageal tumor, GERD, Achalasia, Radiation therapy)
- Anatomical changes in the oral cavity, pharynx and larynx that might interfere with swallowing (i.e.: , history of recent trauma to the nasal cavity or surrounding tissue )
- Patients with tracheostomy or a history of having been submitted to it.
- Patients with contraindications of Flexible Endoscopic Evaluation of Swallowing as severe dyskinesia.
- Severe bleeding disorders and/or recent severe epistaxis, and bilateral obstruction of the nasal passages.
- History of major systemic disease e.g.; renal, hepatic, thyroid diseases, and collagen vascular disorders.
- Non cooperative patients
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities
Read the detailed description
Objectives:
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities
Study Design:
Observational, descriptive study
Population of study and disease condition:
Egyptian patients with Clinically Definite Multiple sclerosis according to the MAGNIMS consensus Guidelines and MCdonald's criteria 2017
Selected patients will be all Multiple Sclerosis patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval (January 2018- June 2018) with an estimate of 100 patients.
A written consent, approved by the ethical committee of Neurology Department, faculty of medicine, Cairo University will be obtained for each participant.
Methodology in details:
Patients in this study will be submitted to the following:
- Through history taking and meticulous neurological examination.
- Clinical \& assessment scales:
- Expanded Disability status scale (EDSS)
- 10-item Dysphagia in Multiple Sclerosis questionnaire (DYMUS): Ten-item questionnaire for assessment of dysphagia in multiple sclerosis. The questionnaire can be divided into two subscales; for the assessment of dysphagia for solids (7 items, in bold), and for the assessment of dysphagia for liquids (3 items, in italics). Instructions for the patient: This questionnaire is about your ability to swallow.
- Dysphagia handicap index (DHI): new, easy-to-complete, statistically robust, patient-reported outcomes measure for assessing the handicapping effect of dysphagia. These statements were 60 in number and were sorted into three subscales based on their content. The emotional subscale consisted of 16 statements representing a person's affective response to their dysphagia. There were 27 statements representing a person's self-perception of physical discomfort due to dysphagia. There were 27 statements representing a person's self-perception of physical discomfort due to dysphagia. In order to evaluate an overall picture of the patient's perception of their dysphagia, all subscales were combined to provide an overall total DHI score. At the completion of the test, subjects were asked to self-rate the severity of their dysphagia on a 7-point equal appearing interval scale.
- Flexible Endoscopic Evaluation of Swallowing (FEES): will be performed to MS patients with dysphagia as detected by dysphagia questionnaires.
- Neuro-imaging: Magnetic Resonance imaging of the brain and spinal cord with contrast were performed for patients on a 1.5 Tesla Phillips Intera® Scanner at the Magnetic Resonance unit, Department of Radio-diagnosis, Cairo University. The following protocols were used:
- T1-weighted images (axial \& sagittal)
- T2-weighted images (axial \& coronal)
- Fluid attenuated inversion recovery (FLAIR) sequence
Correlation of endoscopy result with type of MS (whether RRMS or progressive form), severity of disease (as assessed by EDSS), duration of disease (number of years since first symptom), and lesion load (assessed by MRI)
Possible Risk:
Uncommon complications of FEES as epistaxis and vasovagal attack (very rare).
Primary outcomes:
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval( January 2018 - June 2018)
Secondary outcome parameters (other outcomes to be assessed) To depict neurogenic dysphagia in MS and assessment of its efficiency as a biomarker for disease progression.
Statistical analysis:
Results will be evaluated statistically by Statistical Package for the Social Sciences "SPSS" version 16.
Data will be summarized using mean and standard deviation for quantitative variables and percent for qualitative variables.
Comparison between groups will be done using chi square test for quantitative variables \& ANOVA (analysis of variance).
Multiple comparisons will be done using post Hoc test for normally distributed quantitative variables and parametrical. Mann-Whitney test for not normally distributed quantitative variables.
- Conditions
- Multiple Sclerosis
- Keywords
- Neurogenic Dysphagia, Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What is being measured
The primary outcome is the main question the study is designed to answer.
screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Ten-item questionnaire for assessment of dysphagia in multiple sclerosis (DYMUS). The higher the score the more or worse dysphagia. the score range from 0 - 10. Patient scored 3 or more on DYMUS questionnaire considered to have dysphagia
Measured: January 2018 - June 2018
screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients having dysphagia by questionnaires attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Dysphagia handicap index (DHI). The higher the score the more or worse dysphagia. the score range from 1 - 7. no cut off value
Measured: January 2018 - June 2018
Assessment of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
To assess severity/degree of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Flexible Endoscopic Evaluation of Swallowing (FEES) for MS patients with dysphagia. it measures degree of dysphagia endoscopically, and the higher the score the more or worse dysphagia. no cut off value. the score range from 1 - 15.
Measured: January 2018 - June 2018
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2018
- Study start1 Jan 2018
- Primary completion15 Jun 2018
- Study completion15 Jun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shereen M Fathi,MD, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03552185
- Sponsor's protocol ID
- SF
- Status last verified
- Aug 2018
- First submitted
- 4 May 2018
- Last updated
- 13 Aug 2018
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies
- ClinicalTrials.gov ID
- NCT03552185
- Acronym / sponsor ID
- SF
- Conditions
- Multiple Sclerosis
- Keywords
- Neurogenic Dysphagia, Multiple Sclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 15 Jun 2018 (actual)
- Study completion
- 15 Jun 2018 (actual)
- First posted
- 11 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities
Detailed description
Objectives:
The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities
Study Design:
Observational, descriptive study
Population of study and disease condition:
Egyptian patients with Clinically Definite Multiple sclerosis according to the MAGNIMS consensus Guidelines and MCdonald's criteria 2017
Selected patients will be all Multiple Sclerosis patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval (January 2018- June 2018) with an estimate of 100 patients.
A written consent, approved by the ethical committee of Neurology Department, faculty of medicine, Cairo University will be obtained for each participant.
Methodology in details:
Patients in this study will be submitted to the following:
- Through history taking and meticulous neurological examination.
- Clinical \& assessment scales:
- Expanded Disability status scale (EDSS)
- 10-item Dysphagia in Multiple Sclerosis questionnaire (DYMUS): Ten-item questionnaire for assessment of dysphagia in multiple sclerosis. The questionnaire can be divided into two subscales; for the assessment of dysphagia for solids (7 items, in bold), and for the assessment of dysphagia for liquids (3 items, in italics). Instructions for the patient: This questionnaire is about your ability to swallow.
- Dysphagia handicap index (DHI): new, easy-to-complete, statistically robust, patient-reported outcomes measure for assessing the handicapping effect of dysphagia. These statements were 60 in number and were sorted into three subscales based on their content. The emotional subscale consisted of 16 statements representing a person's affective response to their dysphagia. There were 27 statements representing a person's self-perception of physical discomfort due to dysphagia. There were 27 statements representing a person's self-perception of physical discomfort due to dysphagia. In order to evaluate an overall picture of the patient's perception of their dysphagia, all subscales were combined to provide an overall total DHI score. At the completion of the test, subjects were asked to self-rate the severity of their dysphagia on a 7-point equal appearing interval scale.
- Flexible Endoscopic Evaluation of Swallowing (FEES): will be performed to MS patients with dysphagia as detected by dysphagia questionnaires.
- Neuro-imaging: Magnetic Resonance imaging of the brain and spinal cord with contrast were performed for patients on a 1.5 Tesla Phillips Intera® Scanner at the Magnetic Resonance unit, Department of Radio-diagnosis, Cairo University. The following protocols were used:
- T1-weighted images (axial \& sagittal)
- T2-weighted images (axial \& coronal)
- Fluid attenuated inversion recovery (FLAIR) sequence
Correlation of endoscopy result with type of MS (whether RRMS or progressive form), severity of disease (as assessed by EDSS), duration of disease (number of years since first symptom), and lesion load (assessed by MRI)
Possible Risk:
Uncommon complications of FEES as epistaxis and vasovagal attack (very rare).
Primary outcomes:
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval( January 2018 - June 2018)
Secondary outcome parameters (other outcomes to be assessed) To depict neurogenic dysphagia in MS and assessment of its efficiency as a biomarker for disease progression.
Statistical analysis:
Results will be evaluated statistically by Statistical Package for the Social Sciences "SPSS" version 16.
Data will be summarized using mean and standard deviation for quantitative variables and percent for qualitative variables.
Comparison between groups will be done using chi square test for quantitative variables \& ANOVA (analysis of variance).
Multiple comparisons will be done using post Hoc test for normally distributed quantitative variables and parametrical. Mann-Whitney test for not normally distributed quantitative variables.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Egyptian patients with Clinically Definite Multiple sclerosis according McDonald's criteria 2017 Selected patients will be all Multiple Sclerosis patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval (January 2018- June 2018) with an estimate of 100 patients
Key inclusion criteria (1 listed)
- Patients diagnosed with Multiple Sclerosis
Key exclusion criteria (7 listed)
- Local causes of Dysphagia excluded by proper history taking, proper clinical examination (e.g.; esophageal tumor, GERD, Achalasia, Radiation therapy)
- Anatomical changes in the oral cavity, pharynx and larynx that might interfere with swallowing (i.e.: , history of recent trauma to the nasal cavity or surrounding tissue )
- Patients with tracheostomy or a history of having been submitted to it.
- Patients with contraindications of Flexible Endoscopic Evaluation of Swallowing as severe dyskinesia.
- Severe bleeding disorders and/or recent severe epistaxis, and bilateral obstruction of the nasal passages.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
Time frame: January 2018 - June 2018
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Ten-item questionnaire for assessment of dysphagia in multiple sclerosis (DYMUS). The higher the score the more or worse dysphagia. the score range from 0 - 10. Patient scored 3 or more on DYMUS questionnaire considered to have dysphagia
screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
Time frame: January 2018 - June 2018
To screen the prevalence of neurogenic dysphagia in Egyptian MS patients having dysphagia by questionnaires attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Dysphagia handicap index (DHI). The higher the score the more or worse dysphagia. the score range from 1 - 7. no cut off value
Assessment of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires
Time frame: January 2018 - June 2018
To assess severity/degree of neurogenic dysphagia in Egyptian MS patients attending Neurology Outpatient Clinic \& Neurology Department at Kasr Alainy Hospital within a definite time interval using Flexible Endoscopic Evaluation of Swallowing (FEES) for MS patients with dysphagia. it measures degree of dysphagia endoscopically, and the higher the score the more or worse dysphagia. no cut off value. the score range from 1 - 15.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2018.
- Individual participant dataSharing planned: Undecided
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
screen the prevalence of neurogenic dysphagia in Egyptian MS patients attending Kasr Alainy hospital during specified peroid of time using validated dysphagia Questionnaires (time frame: January 2018 - June 2018). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2018.